All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
The aml Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the aml Hub cannot guarantee the accuracy of translated content. The aml and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The AML Hub is an independent medical education platform, sponsored by Astellas, Daiichi Sankyo, Johnson & Johnson, Kura Oncology and Syndax, and has been supported through educational grants from Bristol Myers Squibb and the Hippocrate Conference Institute, an association of the Servier Group. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out moreCreate an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View AML content recommended for you
On 20th July 2017, in a study published in Leukemia and Lymphoma, Nicholas Short and colleagues from The University of Texas MD Anderson Cancer Center, Houston, Texas, reported findings from their phase I/II randomized study (NCT01289457), which evaluated the safety and efficacy of idarubicin and cytarabine with nucleoside analogues clofarabine (CIA) or fludarabine (FIA) therapy for adults with Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML).
Initially, the optimal dose of clofarabine for the CIA regimen was investigated in the phase I portion of this trial and the recommended phase II dose for clofarabine was established as 15mg/m2 IV daily on days 1–3. In the phase II portion of the study, a total of 81 R/R AML patients were enrolled between August 2011 and April 2014. Patients were randomly assigned to receive either CIA (median age = 54 years [n =48]) and FIA (median age = 57 years [n = 33]).
There were no major differences between the CIA and FIA treatment regimens in terms of AEs and early mortality rates, thus resulting in similar responses and survival rates.
The authors concluded by highlighting that the results of their study suggests that “CIA and FIA are safe and effective salvage treatments” for patients with R/R AML.
The purine nucleoside analogues clofarabine and fludarabine are active in acute myeloid leukemia (AML). We conducted a phase I/II randomized study of idarubicin and cytarabine with either clofarabine (CIA) or fludarabine (FIA) for relapsed or refractory AML. Clofarabine 15 mg/m2 was identified as the recommended phase II dose. Eighty-one patients were assigned using adaptive randomization to CIA (n = 48) or FIA (n = 33). The complete response (CR)/CR without platelet recovery rate did not differ between CIA and FIA (38% versus 30%, respectively; p = .50). In both arms, more than half of patients who had received only one prior line of therapy achieved remission. The median event-free survival for CIA and FIA was 2.0 and 1.9 months (p = .48), and the median overall survival was 6.3 and 4.7 months, respectively (p = .28). No significant differences in adverse events or early mortality rates were observed. Overall, CIA and FIA resulted in similar response rates and survival in patients with relapsed/refractory AML.
References